The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse
_256_384.jpg)
Indian Chemical News, an online news media covering Pharma, Chemical and Petrochemical sector is organizing an E-conference on “India's Pharma Industry Outlook 2021” on 12th February, 2021 from 3:00 PM – 4:30 PM.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
Subscribe To Our Newsletter & Stay Updated
